These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Physicochemical Stability of Monoclonal Antibodies: A Review. Le Basle Y; Chennell P; Tokhadze N; Astier A; Sautou V J Pharm Sci; 2020 Jan; 109(1):169-190. PubMed ID: 31465737 [TBL] [Abstract][Full Text] [Related]
3. Oxidation and Deamidation of Monoclonal Antibody Products: Potential Impact on Stability, Biological Activity, and Efficacy. Gupta S; Jiskoot W; Schöneich C; Rathore AS J Pharm Sci; 2022 Apr; 111(4):903-918. PubMed ID: 34890632 [TBL] [Abstract][Full Text] [Related]
4. Physical Instabilities of Therapeutic Monoclonal Antibodies: A Critical Review. Bana AAK; Mehta P; Ramnani KAK Curr Drug Discov Technol; 2022; 19(6):e240622206367. PubMed ID: 35748546 [TBL] [Abstract][Full Text] [Related]
5. Unique Impacts of Methionine Oxidation, Tryptophan Oxidation, and Asparagine Deamidation on Antibody Stability and Aggregation. Alam ME; Slaney TR; Wu L; Das TK; Kar S; Barnett GV; Leone A; Tessier PM J Pharm Sci; 2020 Jan; 109(1):656-669. PubMed ID: 31678251 [TBL] [Abstract][Full Text] [Related]
6. Deamidation Can Compromise Antibody Colloidal Stability and Enhance Aggregation in a pH-Dependent Manner. Alam ME; Barnett GV; Slaney TR; Starr CG; Das TK; Tessier PM Mol Pharm; 2019 May; 16(5):1939-1949. PubMed ID: 30916563 [TBL] [Abstract][Full Text] [Related]
7. Freeze-thaw characterization process to minimize aggregation and enable drug product manufacturing of protein based therapeutics. Jain K; Salamat-Miller N; Taylor K Sci Rep; 2021 May; 11(1):11332. PubMed ID: 34059716 [TBL] [Abstract][Full Text] [Related]
8. Aggregates in monoclonal antibody manufacturing processes. Vázquez-Rey M; Lang DA Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193 [TBL] [Abstract][Full Text] [Related]
9. Chemical and physical instabilities in manufacturing and storage of therapeutic proteins. Krause ME; Sahin E Curr Opin Biotechnol; 2019 Dec; 60():159-167. PubMed ID: 30861476 [TBL] [Abstract][Full Text] [Related]
10. Stress Temperature Studies in Small Scale Hastelloy® Drug Substance Containers Lead to Increased Extent of and Increased Variability in Antibody-Drug Conjugate and Monoclonal Antibody Aggregation: Evidence for Novel Oxidation-Induced Crosslinking in Monoclonal Antibodies. Klair N; Kim MT; Lee A; Xiao NJ; Patel AR J Pharm Sci; 2021 Apr; 110(4):1615-1624. PubMed ID: 33035540 [TBL] [Abstract][Full Text] [Related]
12. Vapor Phase Hydrogen Peroxide Decontamination or Sanitization of an Isolator for Aseptic Filling of Monoclonal Antibody Drug Product-Hydrogen Peroxide Uptake and Impact on Protein Quality. Hubbard A; Roedl T; Hui A; Knueppel S; Eppler K; Lehnert S; Maa YF PDA J Pharm Sci Technol; 2018; 72(4):348-366. PubMed ID: 29545321 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal Antibody Dimers Induced by Low pH, Heat, or Light Exposure Are Not Immunogenic Upon Subcutaneous Administration in a Mouse Model. Kijanka G; Bee JS; Schenerman MA; Korman SA; Wu Y; Slütter B; Jiskoot W J Pharm Sci; 2020 Jan; 109(1):730-738. PubMed ID: 31029572 [TBL] [Abstract][Full Text] [Related]
14. Oxidation in the complementarity-determining regions differentially influences the properties of therapeutic antibodies. Dashivets T; Stracke J; Dengl S; Knaupp A; Pollmann J; Buchner J; Schlothauer T MAbs; 2016; 8(8):1525-1535. PubMed ID: 27612038 [TBL] [Abstract][Full Text] [Related]
15. Effect of ambient light on IgG1 monoclonal antibodies during drug product processing and development. Sreedhara A; Yin J; Joyce M; Lau K; Wecksler AT; Deperalta G; Yi L; John Wang Y; Kabakoff B; Kishore RS Eur J Pharm Biopharm; 2016 Mar; 100():38-46. PubMed ID: 26707077 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the photodegradation of a human IgG1 monoclonal antibody formulated as a high-concentration liquid dosage form. Qi P; Volkin DB; Zhao H; Nedved ML; Hughes R; Bass R; Yi SC; Panek ME; Wang D; Dalmonte P; Bond MD J Pharm Sci; 2009 Sep; 98(9):3117-30. PubMed ID: 19009595 [TBL] [Abstract][Full Text] [Related]
17. Aggregation and chemical modification of monoclonal antibodies under upstream processing conditions. Dengl S; Wehmer M; Hesse F; Lipsmeier F; Popp O; Lang K Pharm Res; 2013 May; 30(5):1380-99. PubMed ID: 23322133 [TBL] [Abstract][Full Text] [Related]
18. Conformational stability and aggregation of therapeutic monoclonal antibodies studied with ANS and Thioflavin T binding. Kayser V; Chennamsetty N; Voynov V; Helk B; Trout BL MAbs; 2011; 3(4):408-11. PubMed ID: 21540645 [TBL] [Abstract][Full Text] [Related]
19. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations. Gikanga B; Hui A; Maa YF PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532 [TBL] [Abstract][Full Text] [Related]
20. Effect of photo-degradation on the structure, stability, aggregation, and function of an IgG1 monoclonal antibody. Shah DD; Zhang J; Maity H; Mallela KMG Int J Pharm; 2018 Aug; 547(1-2):438-449. PubMed ID: 29883793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]